| I-59 Itziar Irurzun Arana Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer Wednesday 10:00-11:30 |
| I-59 Itziar Irurzun Arana Population PK modelling of camizestrant, a next-generation oral selective estrogen receptor degrader, as monotherapy and in combination with palbociclib in ER+/HER2- advanced breast cancer Wednesday 10:00-11:30 |